Liquidia Faces Patent Litigation Filed by United Therapeutics

MT Newswires Live

May 12, 2025

Liquidia (LQDA) said Monday that United Therapeutics (UTHR) has filed a complaint Friday accusing the company of infringing United's patent.

The complaint, filed in the US District Court for the Middle District of North Carolina, also seeks to enjoin Liquidia from commercializing Yutrepia, or treprostinil inhalation power, if the US Food and Drug Administration approves it for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Liquidia Chief Executive Roger Jeffs said the company has previously invalidated similar claims covering the treatment of pulmonary hypertension patients with inhaled treprostinil.

The company said United Therapeutics is not currently seeking an injunction against the FDA, which had set a Prescription Drug User Fee Act goal date of May 24 to prevent final approval of the new drug application for Yutrepia.

United Therapeutics did not immediately respond to a request for comment from MT Newswires.

Price: 15.46, Change: +0.20, Percent Change: +1.31

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2534276453"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2534276453\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2534276453?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-12 21:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534276453","market":"fut","top_or_hot":-1,"title":"Liquidia Faces Patent Litigation Filed by United Therapeutics","media":"MT Newswires Live","content":"<html><body><p> Liquidia (LQDA) said Monday that United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (UTHR) has filed a complaint Friday accusing the company of infringing United's patent.</p><p>The complaint, filed in the US District Court for the Middle District of North Carolina, also seeks to enjoin Liquidia from commercializing Yutrepia, or treprostinil inhalation power, if the US Food and Drug Administration approves it for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.</p><p>Liquidia Chief Executive Roger Jeffs said the company has previously invalidated similar claims covering the treatment of pulmonary hypertension patients with inhaled treprostinil.</p><p>The company said United Therapeutics is not currently seeking an injunction against the FDA, which had set a Prescription Drug User Fee Act goal date of May 24 to prevent final approval of the new drug application for Yutrepia.</p><p>United Therapeutics did not immediately respond to a request for comment from MT Newswires.</p><p>Price: 15.46, Change: +0.20, Percent Change: +1.31</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liquidia Faces Patent Litigation Filed by United Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiquidia Faces Patent Litigation Filed by United Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-12 21:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Liquidia (LQDA) said Monday that United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (UTHR) has filed a complaint Friday accusing the company of infringing United's patent.</p><p>The complaint, filed in the US District Court for the Middle District of North Carolina, also seeks to enjoin Liquidia from commercializing Yutrepia, or treprostinil inhalation power, if the US Food and Drug Administration approves it for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.</p><p>Liquidia Chief Executive Roger Jeffs said the company has previously invalidated similar claims covering the treatment of pulmonary hypertension patients with inhaled treprostinil.</p><p>The company said United Therapeutics is not currently seeking an injunction against the FDA, which had set a Prescription Drug User Fee Act goal date of May 24 to prevent final approval of the new drug application for Yutrepia.</p><p>United Therapeutics did not immediately respond to a request for comment from MT Newswires.</p><p>Price: 15.46, Change: +0.20, Percent Change: +1.31</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2534276453","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534276453","pubTimestamp":1747057929,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Liquidia  said Monday that United Therapeutics  has filed a complaint Friday accusing the company of infringing United's patent.The complaint, filed in the US District Court for the Middle District of North Carolina, also seeks to enjoin Liquidia from commercializing Yutrepia, or treprostinil inhalation power, if the US Food and Drug Administration approves it for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.Liquidia Chief Executive Roger Jeffs said the company has previously invalidated similar claims covering the treatment of pulmonary hypertension patients with inhaled treprostinil.The company said United Therapeutics is not currently seeking an injunction against the FDA, which had set a Prescription Drug User Fee Act goal date of May 24 to prevent final approval of the new drug application for Yutrepia.United Therapeutics did not immediately respond to a request for comment from MT Newswires.Price: 15.46, Cha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LQDA":"Liquidia Technologies Inc","BK4139":"生物科技","BK4007":"制药","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","UTHR":"美国联合医疗","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4532":"文艺复兴科技持仓"},"translate_title":"Liquidia面临United Therapeutics提起的专利诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":0.9,"UTHR":1},"content_text":"Liquidia (LQDA) said Monday that United Therapeutics (UTHR) has filed a complaint Friday accusing the company of infringing United's patent.The complaint, filed in the US District Court for the Middle District of North Carolina, also seeks to enjoin Liquidia from commercializing Yutrepia, or treprostinil inhalation power, if the US Food and Drug Administration approves it for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.Liquidia Chief Executive Roger Jeffs said the company has previously invalidated similar claims covering the treatment of pulmonary hypertension patients with inhaled treprostinil.The company said United Therapeutics is not currently seeking an injunction against the FDA, which had set a Prescription Drug User Fee Act goal date of May 24 to prevent final approval of the new drug application for Yutrepia.United Therapeutics did not immediately respond to a request for comment from MT Newswires.Price: 15.46, Change: +0.20, Percent Change: +1.31","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}